

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Michel REVEL et al.

Art Unit: 1646

Application No.: 09/462,416

Conf. No. 5069

Examiner: Nirmai S. Basi

Filed: April 13, 2002

Washington, D.C.


For: CHIMERIC INTERLEUKIN-6 SOLUBLE RECEPTOR/LIGAND PROTEIN ANALOGS...

Atty.'s Docket: REVEL=15

Date: July 10, 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:



RECEIVED

JUL 17 2002

TECH CENTER 1600/2900

Transmitted herewith is a [XX] Amendment []

in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 18	MINUS	** 20		0
INDEP.	* 1	MINUS	*** 3		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 42	\$
+ 140	\$
ADDITIONAL FEE TOTAL	
	\$

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 84	\$
+ 280	\$
TOTAL	
	\$

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
[] Second - \$ 200.00
[] Third - \$ 460.00
[] Fourth - \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[xx] First - \$ 110.00
[] Second - \$ 400.00
[] Third - \$ 920.00
[] Fourth - \$ 1440.00

Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$

[XX] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$110.00

[] A check in the amount of \$ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

#141D
Temp
7/18/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Atty. Docket: REVEL=15

In re Application of JUL 10 2002)
Michel REVEL et al.)
Appln. No.: 09/462,416)
Filed: April 13, 2000)
For: CHIMERIC INTERLEUKIN-6)
SOLUBLE RECEPTOR/LIGAND)
PROTEIN, ANALOGS...)

Conf. No.: 5069
Art Unit: 1646
Examiner: Nirmal S. Basi
Washington, D.C.
July 10, 2002

AMENDMENT

RECEIVED
JUL 17 2002
TECH CENTER 1600/2900

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of January 15, 2002, petition for a 3-month of time and payment being attached hereto, please amend as follows:

In the Specification:

Please replace the paragraph beginning at page 12, line 19, with the following rewritten paragraph:

71 -- Figure 1 (A, B, C) depicts a schematic representation of the various vectors, reagents and process steps used in the construction of the chimeric DNA molecule encoding a chimeric protein in which is conserved the structure of the natural form of sIL-6R ending at the Val 356 residue followed by the sequence of the natural, mature, processed form of IL-6 as detailed in Example 1. In Fig. 1A,